Quality of Life and Side Effects in Patients with Actinic Keratosis Treated With Ingenol Mebutate: A Pilot Study

详细信息    查看全文

• 作者：E. Jubert-Esteve^a ; L.J. del Pozo-Hernando^a ; ^{lpozoh@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; N. Izquierdo-Herce^a ; A. Bauzá ; -Alonso^a ; A. Martí ; n-Santiago^a ; M. Jones-Caballero^b
• 关键词：Actinic keratosis ; Ingenol mebutate ; Skindex-29 ; TSMQ 1.4 ; Side effects
• 刊名：Actas Dermo-Sifiliográficas
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：106
• 期：8
• 页码：644-650
• 全文大小：380 K

文摘

Actinic keratosis (AK) lesions are in situ squamous cell carcinoma. These lesions have a low risk of progressing to invasive disease but significant impact on patients’ quality of life (QoL). The aim of this study was to assess QoL and side effects in patients with AK receiving treatment with ingenol mebutate.

Material and methods

This was a prospective, non-randomized pilot study carried out in Spain. The target population was adults with a clinical diagnosis of AK affecting any part of the body. Outcomes were assessed on the basis of a QoL questionnaire (Skindex-29), local skin response, the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4), and clinical response.

Results

A total of 19 patients were studied. Most of the participants were men (89.5%) and mean age was 76.2 years. After treatment with ingenol mebutate, significant improvement was observed in the Skindex-29 subscales relating to symptom severity (P = .041), the patients’ emotional state (P = .026), and in the overall score (P = .014). Erythema, crusting, and flaking or scaling were the local skin responses with highest median score (2.0 in all 3 cases). Imiquimod 5% and ingenol mebutate achieved higher median scores for effectiveness and global satisfaction than any other previous treatments (as measured by TSQM 1.4). In the patients’ assessment of convenience, ingenol mebutate had a higher median score than previous treatments. Over half of the patients (52.6%) had an improvement of at least 75% at month 3.

Conclusions

QoL in patients with AK improves after treatment with ingenol mebutate. The presence of side effects did not affect QoL or patient satisfaction with treatment.